Search

Displaying results 3091 - 3100 of 5451 in total
  1. Drug

    Poliovirus type 1 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10795
    ApprovedInvestigational

    Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The v...

    Mixtures: Dt Polio Adsorbed - Sus Im
  2. Drug

    Poliovirus type 3 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10797
    ApprovedInvestigational

    Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 3. The v...

    Mixtures: Dt Polio Adsorbed - Sus Im
  3. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. … It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.

    Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamideProducts: INLYTA TABLETS 1MG, INLYTA TABLETS 5MG
  4. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain . The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique ...

  5. Drug

    Delavirdine

    go.drugbank.com/drugs/DB00705
    ApprovedInvestigationalWithdrawn

    A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.

  6. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.

  7. Drug

    Aluminum zirconium pentachlorohydrex gly

    go.drugbank.com/drugs/DB11277
    ApprovedWithdrawn

    It is a coordination complex of Aluminum Zirconium pentachlorohydrate and glycine. Its anhydrous form allows the molecule to absorb moisture.

  8. Drug

    Iodixanol

    go.drugbank.com/drugs/DB01249
    Approved

    Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the

    Products: VISIPAQUE 320 MG I /ML, VISIPAQUE 270 MG/ML IA IV İNTRATEKAL ENJEKSİYON İÇİN ÇÖZELTİ İÇEREN FLAKON, 50 ML
  9. Drug

    Moxifloxacin

    go.drugbank.com/drugs/DB00218
    ApprovedInvestigational

    Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

    Products: MOXIFLOXACINA DOUBLE-E PHARMA, T & B
  10. Drug

    Dioctyldimonium

    go.drugbank.com/drugs/DB13970
    Approved

    Mixtures: Quick Defense 4m Disinfectant Wipes